Skip to content

ImmunityBio, Inc. (IBRX) — Institutional Holders & Catalysts | BiotechEdge

Catalysts Convergence Squeeze Signals Runway Insiders Research

Sign In Start Free Trial

Home›Companies›ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc.

IBRX

Held by 1 specialist biotech fund

1 fund opened new positions.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

1.5/10

1 fund opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback Terms Privacy Disclaimer

●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Tang Capital ManagementNew

Catalysts

No catalysts tracked.

Position Details

Tang Capital ManagementNEWFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

ABEO1 fund ACAD1 fund ACET1 fund ALT1 fund ANAB1 fund ANIP1 fund ARVN1 fund AVIR1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: